THUNDERCOMM
14.3.2023 05:13:40 CET | Business Wire | Press release
Thundercomm, a leading global supplier of smart Internet of Things (IoT) modules, announced today that its new-generation of 5G cellular module the TurboXT62G-EA has been certified by Deutsche Telekom, leading carrier in Europe. Being the industry’s leading cellular module, TurboX T62G-EA SOM is based on the innovative Snapdragon® X62 5G Modem-RF System, has already achieved both regulatory CE and KC certification for Europe and Korean, and carrier approvals of Deutsche Telekom and KT. Snapdragon X62 is designed to extend 5G in more applications, including IoT. TurboX T62G-EA enables customers to immediately deploy into a diverse range of high end IoT devices across Europe and Korea, such as MIFI, gateway/CPE/routers, high resolution vide transmission, online entertainment, robotics, AR/VRs, remote control/drones etc.
Targeting European and Asian markets, the T62G-EA SOM is a highly-integrated global 5G Sub-6GHz, supporting both SA and NSA modes, LTE and WCDMA bands. With footprint of 42mm x 45mm x 2.65mm, T62G-EA provides a plentiful peripheral interface such as UART/USB/I2C/I2S/PCI-e etc. MIFI and CPE reference design and development kits are available based on T62G-EA, aiming to help customers shorten the time to market.
Besides working with external hosts with different operating systems, Windows, Linux Ubuntu, Android etc. T62G-EA also supports comprehensive SDK which helps customers to work in Open CPU way, This is also part of turnkey software kits that offer end customers the best development experience on top of hardware functionalities.
T62G-EA SOM is one form factor of the T62 SOM series. The other variant is T62M-EA, which supports 5G Sub-6GHz/4G/3G and targets for laptop, notebook, CPE and router applications, will be available for Japanese and European markets soon.
“Thundercomm is continuously investing in 5G, as we believe it’s an essential part of connected world, where we see the increasing numbers and requirement of 5G-capable devices,” said Hiro Cai, CEO at Thundercomm. “ Thundercomm will work closely with global telecom operators, leveraging our expertise in 5G CPE design and performance tunning, to meet the requirements of global customers.”
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Snapdragon is a trademark or registered trademark of Qualcomm Incorporated.
Snapdragon branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005865/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom